Royal Philips (NYSE:PHG) today released data from a study of automated 3D echocardiogram analyses with its HeartModel A.I. ultrasound software, touting it as an accurate alternative to conventional methodology.
Results from the study were published in the European Heart Journal.
The study aimed to explore the accuracy and reproducibility of left atrial volume, left ventricular volume and ejection fraction measurements. A total of 180 patients were imaged in the study across 6 sites using 3DE with Philips’ EPIQ ultrasound systems and analyzed with the HeartModel AI software, the company said.
“The days of time-consuming, difficult collection and analysis of heart measurements are behind us. The results of this study provide further evidence that 3DE technology like Philips HeartModelA.I. is the way forward for global health systems to save time and gather accurate data for quality care delivery to patients,” Dr. Roberto Lang of the University of Chicago Medicine said in a prepared statement.
Findings indicated that different operating physicians were able to obtain accurate and reproducible automated analyses of all the 3 heart measurements included in the study. Philips claims that the results demonstrate that its HeartModel AI can be save time and yield consistent, reproducible results
“It’s exciting to see the impact of the Philips EPIQ system and HeartModelA.I. software at work around the world. With these tools, Philips is empowering clinicians with diagnostic confidence and facilitating wider adoption of innovative technology for cardiac imaging,” Philips cardiovascular ultrasound senior medical director Dr. Alexandra Gonçalves said in a press release.
Late last month, Philips saw shares rise nearly 5% after the medical device and healthcare product maker posted 1st quarter earnings that beat expectations on The Street, despite weak sales growth.